Gasser T, Sandalcioglu I E, El Hamalawi B, van de Nes J A P, Stolke D, Wiedemayer H
Department of Neurosurgery, Klinik und Poliklinik für Neurochriurgie, Universitätsklinikum Essen, Hufelandstrasse 55, D-45122 Essen, Germany.
J Neurooncol. 2005 Jun;73(2):163-8. doi: 10.1007/s11060-004-4275-5.
Intramedullary spinal cord metastases (ISCM) of systemic cancer are rare. To date, patients with ISCM tend to benefit only to a limited extend from surgery and adjuvant therapy. Subject of this investigation is to assess predictive factors for surgical outcome and survival and to evaluate the value of surgical radicality in the treatment of ISCM.
Between 1990 and 2004, a series of 146 patients with intramedullary tumors underwent surgical treatment in our institution. Among these, 13 patients with intramedullary cancer metastases (7 adenocarcinomas, 3 poorly differentiated carcinomas, 3 sarcomas) were identified. Standard microsurgical removal of the ISCM was performed. Functional outcome was graded according to a standardized scale and factors influencing outcome and survival were statistically analyzed.
Median progression-free survival was 13 weeks and median overall survival was 31 weeks. In 5 patients (38) the intramedullary lesion was the initial manifestation of the malignant disease. All poorly differentiated carcinomas and all sarcomas were resected incompletely. Surgical radicality presented a negative predictive factor for functional outcome, increasing radicality leading to functional deterioration. Age, sex, tumor localization, surgical radicality and the presence of neoplastic meningeosis did not affect survival.
Surgery of ISCM can be performed with an acceptable operative morbidity. Radicality depended on tumor histology. However, radical tumor removal did not affect survival and was correlated with a poor functional outcome. Therefore, complete surgical removal of ISCM should only be intended in patients in whom an unproblematic excision is feasible.
系统性癌症的脊髓髓内转移瘤(ISCM)较为罕见。迄今为止,ISCM患者从手术和辅助治疗中获得的益处往往有限。本研究的目的是评估手术结果和生存的预测因素,并评估手术根治性在ISCM治疗中的价值。
1990年至2004年间,我院对146例髓内肿瘤患者进行了手术治疗。其中,确诊为13例髓内癌转移患者(7例腺癌、3例低分化癌、3例肉瘤)。对ISCM进行了标准的显微手术切除。根据标准化量表对功能结果进行分级,并对影响结果和生存的因素进行统计学分析。
无进展生存期的中位数为13周,总生存期的中位数为31周。5例患者(38%)的髓内病变是恶性疾病的初始表现。所有低分化癌和所有肉瘤均未完全切除。手术根治性是功能结果的负面预测因素,根治性增加导致功能恶化。年龄、性别、肿瘤定位、手术根治性和肿瘤性脑膜病变的存在不影响生存。
ISCM手术的手术发病率可接受。根治性取决于肿瘤组织学。然而,肿瘤的根治性切除并不影响生存,且与功能结果不佳相关。因此,仅应在可行无问题切除的患者中考虑完全手术切除ISCM。